<p>(A) Median OS was 73.5 months for <i>IDH1</i> mutated gliomas and 32 months for <i>IDH1</i> wild type gliomas (p = 0.015, Log-rank test). (B) Median PFS was 34.9 months for <i>IDH1</i> mutated gliomas and 16 months for <i>IDH1</i> wild type gliomas (p = 0.006, Log-rank test).</p
<p>A: Kaplan-Meier analysis showing the OS of high-grade glioma patients with wild-type (blue line) ...
a<p><i>P</i> value of Q-test for heterogeneity test.</p>b<p>Random-effects model was used when <i>P<...
Kaplan-Meier survival curves for WHO grade III or IV glioma according to use of statins or aspirin.<...
<p>(A) Median OS was 65 months for <i>IDH1</i> mutated astrocytomas and 23 months for <i>IDH1</i> wi...
<p>A comparison of PFS and overall survival (OS) according to (A and B, respectively) pathological (...
<p>A comparison of (A) overall survival (OS) and (B) progression-free survival (PFS) between patient...
Kaplan-Meier curves illustrate the different survival patterns of PRAME-negative and PRAME-positive ...
Kaplan-Meier curves compare the survivorship of PRAME-positive and PRAME-negative tumors in IDH-muta...
Kaplan-Meier curves compare the survivorship of PRAME-positive and PRAME-negative tumors in IDH-muta...
Kaplan-Meier curves compare the survivorship of PRAME-positive and PRAME-negative tumors in IDH-muta...
<p>Patients with low-perfused gliomas had significantly longer EFS compared to patients with high-pe...
<p>The top three panels are genes having low-levels gains or high-level amplifications (magenta) com...
<p>Kaplan-Meier curve for overall survival in patients with mutant EGFR mutation versus those with w...
PURPOSE: This retrospective study aimed to correlate F-FDG uptake on PET/CT with isocitrate dehydrog...
Background: Magnetic resonance imaging (MRI), digital pathology imaging (PATH), demographics, and ID...
<p>A: Kaplan-Meier analysis showing the OS of high-grade glioma patients with wild-type (blue line) ...
a<p><i>P</i> value of Q-test for heterogeneity test.</p>b<p>Random-effects model was used when <i>P<...
Kaplan-Meier survival curves for WHO grade III or IV glioma according to use of statins or aspirin.<...
<p>(A) Median OS was 65 months for <i>IDH1</i> mutated astrocytomas and 23 months for <i>IDH1</i> wi...
<p>A comparison of PFS and overall survival (OS) according to (A and B, respectively) pathological (...
<p>A comparison of (A) overall survival (OS) and (B) progression-free survival (PFS) between patient...
Kaplan-Meier curves illustrate the different survival patterns of PRAME-negative and PRAME-positive ...
Kaplan-Meier curves compare the survivorship of PRAME-positive and PRAME-negative tumors in IDH-muta...
Kaplan-Meier curves compare the survivorship of PRAME-positive and PRAME-negative tumors in IDH-muta...
Kaplan-Meier curves compare the survivorship of PRAME-positive and PRAME-negative tumors in IDH-muta...
<p>Patients with low-perfused gliomas had significantly longer EFS compared to patients with high-pe...
<p>The top three panels are genes having low-levels gains or high-level amplifications (magenta) com...
<p>Kaplan-Meier curve for overall survival in patients with mutant EGFR mutation versus those with w...
PURPOSE: This retrospective study aimed to correlate F-FDG uptake on PET/CT with isocitrate dehydrog...
Background: Magnetic resonance imaging (MRI), digital pathology imaging (PATH), demographics, and ID...
<p>A: Kaplan-Meier analysis showing the OS of high-grade glioma patients with wild-type (blue line) ...
a<p><i>P</i> value of Q-test for heterogeneity test.</p>b<p>Random-effects model was used when <i>P<...
Kaplan-Meier survival curves for WHO grade III or IV glioma according to use of statins or aspirin.<...